E-26 | Transcatheter Aortic Valve Replacement with Edwards Sapien and Medtronic CoreValve in End Stage Renal Disease: A Contemporary Assessment

Transcatheter aortic valve replacement (TAVR) has emerged as a vital intervention for patients with severe symptomatic aortic stenosis, especially those at high surgical risk like those with end-stage renal disease (ESRD). We sought to compare the outcomes of two widely used TAVR valves – the Edwards Sapien valve and the Medtronic CoreValve in ESRD (Stage 5 or dialysis) patients. Data was collected for quality assurance on all patients that underwent TAVR between 2021-2022 at 4 New York metropolitan area hospitals. Data on all patients was entered into the STS ACC TAVR registry. Bleeding was classified according to the Valve Academic Research Consortium (VARC). A p-value <0.05 was considered statistically significant. From 2021 to 2022, a total of 125 ESRD patients were identified, 85 treated with the Sapien valve and 40 the Medtronic valve. Baseline characteristics were similar between the two groups (Table). In hospital outcomes were similar between the two groups, except for a higher rate of VARC 2 bleeding complications and pacemaker implantation in patients treated with the Medtronic valve. In ESRD patients undergoing TAVR, in hospital outcomes were excellent in this very high-risk group of patients. Both valves can be considered viable options for TAVR. Future investigation is needed on long-term outcomes and the impact of valve choice on the quality of life in ESRD patients.